ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0735

Facilitators and Barriers to Weekly Monitoring of Disease Activity with Electronic Patient Reported Outcomes: A Focus Group Study of Patients with Inflammatory Arthritis

Jim Wiegel1, Bart Seppen2, Michael Nurmohamed3, Marieke ter Wee4 and Wouter Bos1, 1Reade Rheumatology Center, Amsterdam, Netherlands, 2Vrije Universiteit | Reade, Amsterdam, Netherlands, 3Amsterdam University Medical Center, Kortenhoef, Netherlands, 4Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, Netherlands

Meeting: ACR Convergence 2022

Keywords: Autoinflammatory diseases, health behaviors, Health Services Research, Patient reported outcomes, Qualitative Research

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Health Services Research Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Telemonitoring disease activity with electronic patient reported outcomes (ePRO’s) may reduce the workload of rheumatic care by decreasing outpatient clinic visits. However, low adherence to reporting ePRO’s is frequently observed which opposes the adoption and benefits of telemonitoring. The objective here is to identify facilitators and barriers to weekly monitoring of disease activity with ePRO’s, which could ultimately be used to optimize the adherence of telemonitoring disease activity.

Methods: Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) that recently participated in one of the two telemonitoring studies with ePRO’s (SEMORA trial or DICODE cohort) were invited to participate in focus group discussions (FGD). In both studies, patients used the ‘MijnReuma Reade’ smartphone application to report a weekly modified Multidimensional Health Assessment Questionnaire (mdHAQ) that includes the Routine Assessment of Patient Index Data 3 (RAPID3). Thematic analysis identified factors to continue or stop telemonitoring disease activity.

Results: A total of 22 patients participated in three focus group discussions, of which 16 (73%) were diagnosed with RA, 4 (18%) with PsA, and 2 (9%) with AS. Mean age was 64 years (SD 10) and 12 (55%) were women. The analysis identified 7 themes and 5 subthemes (see figure 1). 1) Improved insight into the disease activity was a facilitator to continue monitoring of disease activity, while 2) experiencing no benefits from reporting ePRO’s acted as a barrier. 3) Providing a clear picture of the rheumatic disease activity was important for patients, but some questions were perceived too general, resulting that non-rheumatic symptoms could influence the results, what patients experienced as a barrier. 4) Discussing the results with their rheumatologist during outpatient clinic visits acted as a facilitator; but patients got discouraged when the results were not discussed. 5) Questionnaire frequency was a facilitator when the disease activity was high or fluctuating, but a barrier when it was low or stable. 6) Importance of a physical appointment acted as a facilitator when the consequence of reporting ePRO’s was skipping a clinic visit. However, some patients stressed the importance of physical appointments, irrespective of the severity of the disease activity. The 7) user experience acted as a barrier when patients encountered bugs with the app, but the low effort of reporting the ePRO, and prompt notifications when a new ePRO was available were facilitators.

Conclusion: The results suggest that providing patients a clear benefit from providing ePROs such as skipping visits; tailoring questionnaire frequency to disease activity; using disease specific ePRO’s; training rheumatologists in communicating ePRO results during consultations; and optimizing the user experience of the used app could be successful strategies to improve adherence to telemonitoring disease activity with ePRO’s.

Supporting image 1

Figure 1. The themes and subthemes emerged from the thematic analysis.


Disclosures: J. Wiegel, None; B. Seppen, None; M. Nurmohamed, AbbVie/Abbott; M. ter Wee, None; W. Bos, Pfizer, Sanofi, Novartis.

To cite this abstract in AMA style:

Wiegel J, Seppen B, Nurmohamed M, ter Wee M, Bos W. Facilitators and Barriers to Weekly Monitoring of Disease Activity with Electronic Patient Reported Outcomes: A Focus Group Study of Patients with Inflammatory Arthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/facilitators-and-barriers-to-weekly-monitoring-of-disease-activity-with-electronic-patient-reported-outcomes-a-focus-group-study-of-patients-with-inflammatory-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/facilitators-and-barriers-to-weekly-monitoring-of-disease-activity-with-electronic-patient-reported-outcomes-a-focus-group-study-of-patients-with-inflammatory-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology